Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced grant of U.S. Patent No. 12,357,590, titled “BINGE BEHAVIOR REGULATORS,” by the USPTO.
The patent builds on U.S. Patent No. 12,350,242 and expands intellectual property protection around the MEAI molecule for regulating binge behaviors and compulsive disorders.
Positive
- New U.S. Patent No. 12,357,590 granted for binge behavior regulators
- Patent strengthens IP protection around MEAI (5-methoxy-2-aminoindane) and related derivatives
- Portfolio now covers regulating binge behaviors including excessive drinking, eating and other compulsive disorders
- Company states it has one of the sector’s most comprehensive global IP portfolios
Negative
- None.
News Market Reaction – CMND
In the Jun 29 session, CMND declined 3.36%, reflecting a moderate negative market reaction. Argus tracked a peak move of +30.0% during that session. Argus tracked a trough of -26.0% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | Clinical milestone | Positive | -4.6% | Completed Part A treatment for 24 participants in Phase I/II AUD trial. |
| Jun 18 | U.S. patent grant | Positive | -2.9% | Granted U.S. patent 12,350,242 for MEAI‑based binge behavior regulators. |
| Jun 16 | Clinical dosing update | Positive | -6.8% | Completed dosing for all 24 participants in Part A CMND‑100 AUD trial. |
| Jun 05 | Webinar / data review | Positive | +36.8% | Announced “Inside MEAI” webinar to review early CMND‑100 clinical data. |
| May 29 | Patent portfolio update | Positive | +46.1% | Japanese patent publication for MEAI‑based depression treatment expanding IP. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical and patent milestones have often seen mixed to negative next‑day reactions, with only occasional strong rallies on IP or event‑driven news.
Key Terms
uspto regulatory
neuroplastogen-derived medical
2-aminoindan medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has been egranted an additional U.S. Patent, No. 12,357,590, titled "BINGE BEHAVIOR REGULATORS", by the United States Patent and Trademark Office (USPTO).
This latest patent builds directly on the Company’s previously issued U.S. Patent No. 12,350,242 and further strengthens its intellectual property protection around the MEAI (5-methoxy-2-aminoindane) molecule and related 2-aminoindan derivatives for regulating binge behaviors, including excessive drinking, eating, and other compulsive disorders.
With this grant Clearmind Medicine strengthens what it believes is one of the sector’s most comprehensive global intellectual property portfolios.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
